Pegylation: a novel process for modifying pharmacokinetics.
about
PEGylation of Interferon-β-1aProfile of certolizumab and its potential in the treatment of psoriatic arthritisPEGylated Adenoviruses: From Mice to MonkeysInhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein.Nanocarriers Usage for Drug Delivery in Cancer TherapyProtein corona - from molecular adsorption to physiological complexityInterferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in MiceNew developments in the treatment of hepatitis CLiposomes as nanomedical devicesThe mechanism of action of interferon-β in relapsing multiple sclerosisPharmaceutical and toxicological properties of engineered nanomaterials for drug deliveryGlycoengineering of interferon-β 1a improves its biophysical and pharmacokinetic propertiesIncidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Therapeutic alpha-interferons protein: structure, production, and biosimilar.Review on photoacoustic imaging of the brain using nanoprobesMechanistic and quantitative insight into cell surface targeted molecular imaging agent design.Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study.Gastrointestinal biodurability of engineered nanoparticles: Development of an in vitro assayPreclinical molecular imaging of tumor angiogenesis.18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression.Intracellular trafficking and subcellular distribution of a large array of HPMA copolymers.A brain-sparing diphtheria toxin for chemical genetic ablation of peripheral cell lineages.Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate.An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.Immunogenicity and other problems associated with the use of biopharmaceuticals.Safety, Tolerability, and Immunogenicity of InterferonsA Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C Patients.PEGylation of interleukin-10 for the mitigation of enhanced pain states.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety.Deciphering the kinetic binding mechanism of dimeric ligands using a potent plasma-stable dimeric inhibitor of postsynaptic density protein-95 as an example.Toward a molecular understanding of nanoparticle-protein interactionsPolyethylene glycol (PEG) linked to near infrared (NIR) dyes conjugated to chimeric anti-carcinoembryonic antigen (CEA) antibody enhances imaging of liver metastases in a nude-mouse model of human colon cancer.Evaluation of in vitro cytotoxic activity of mono-PEGylated StAP3 (Solanum tuberosum aspartic protease 3) forms.Targeting gold nanocages to cancer cells for photothermal destruction and drug deliveryTailoring polymersome bilayer permeability improves enhanced permeability and retention effect for bioimaging.Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B.A coarse-grained model for polyethylene oxide and polyethylene glycol: conformation and hydrodynamics.In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulationEffects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
P2860
Q22241420-D5465C84-FB35-457E-953C-B82110036539Q22305856-9C856533-67FB-4204-8942-122D18997562Q24635276-77C9AB6D-BC45-4D8B-BE12-4E47DD508E99Q24814238-A284FB36-F5ED-4BEF-8CD5-5680007008A8Q26740048-2E5F7C4E-C033-4368-BEAE-30EB1C7D4AC8Q26853351-99B04E46-11B7-4E90-AF7B-38BFE93BB47BQ27473398-00CD2BEF-662A-4E3C-AEE4-394B46363061Q27477964-802732B1-3365-44B0-8F6B-997C05166195Q28088315-03842794-978A-4D71-9C54-97D0CD56B397Q28239752-3ED424EE-2485-41AA-836F-863EFFC18FCEQ28396383-1C0F22F7-B576-4EB8-B606-6F82FEA24FCAQ28539087-72C65CBA-4272-4787-BF4E-97B6AA6E5F69Q30235581-40A70A5B-1C07-45B5-BF5A-5BBC34473E8AQ30361968-F0C3B8E8-E37A-4A41-AA78-4DE804207C6FQ30366218-2C03D9CE-4A37-4793-9FEE-313520F3D02FQ30383551-D28CC25F-7D88-4935-9FA9-F1C358405AB4Q30406070-0F97114F-8375-4269-90E5-CE644BD1F8A3Q30431391-ADBA7016-AAF4-4F66-A56F-E915EE5E54E8Q30475818-0749B9CE-C7DC-4F69-BD89-6875C574537FQ30497615-988E4DAB-0C05-4392-B99C-31343D66396EQ30502459-BAA4FCDF-3921-4AC3-BCFA-68C2536F1A5FQ30844300-64929D66-4B30-4248-AA3B-6A71D66E4EA9Q33347186-F8DB9BCF-D00F-4AA5-AD11-0E92BB6A996DQ33412963-A4661258-1C8C-4342-9AE3-B266C55FE6A1Q33416851-A9F12E6F-F7FB-461E-BD68-3A7C0F156A90Q33435810-C153B10F-A488-460C-9300-EF85DB2F223EQ33440863-8866A7F1-6750-42A4-B223-DF6065A2F5F4Q33505369-DEA5738B-F93D-4FC7-95F4-E58D16E80C33Q33559298-70BFD2EC-8DE9-4B2E-8C68-766FAA1F49B9Q33582600-6D6E71D2-7587-474A-8959-97FBB0AA89F4Q33615585-A48FD30F-6088-48D5-A8B8-41EF352C38F1Q33639595-1B7C493D-49F2-4EC8-80FE-699BEB671FD2Q33654731-DFD1AE52-ABA5-4302-B254-535CE4AC6C71Q33783104-EC3548AE-756E-4D03-B649-0BE9F9F924BDQ33805083-4DC1B5B8-CF6D-4C47-9F04-C62CF1CDFA2DQ33893586-0D9B1CAB-FE9E-4EE9-B743-20E0D39A3D1FQ33989405-430FDA14-FC21-4E39-996B-610C62D1875FQ34120971-D1A7BB60-370A-4E77-8641-9C3C971E3909Q34151598-C28D280C-AF30-4408-92E7-1F641D487BB4Q34225751-9A27BE9C-2990-4C27-8226-6B9203347A02
P2860
Pegylation: a novel process for modifying pharmacokinetics.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pegylation: a novel process for modifying pharmacokinetics.
@ast
Pegylation: a novel process for modifying pharmacokinetics.
@en
Pegylation: a novel process for modifying pharmacokinetics.
@nl
type
label
Pegylation: a novel process for modifying pharmacokinetics.
@ast
Pegylation: a novel process for modifying pharmacokinetics.
@en
Pegylation: a novel process for modifying pharmacokinetics.
@nl
prefLabel
Pegylation: a novel process for modifying pharmacokinetics.
@ast
Pegylation: a novel process for modifying pharmacokinetics.
@en
Pegylation: a novel process for modifying pharmacokinetics.
@nl
P2093
P1476
Pegylation: a novel process for modifying pharmacokinetics.
@en
P2093
P304
P356
10.2165/00003088-200140070-00005
P577
2001-01-01T00:00:00Z
P5875
P6179
1022854020